CP-Reta 20mg

Description

CP-Reta 20mg is supplied as lyophilized powder with a labeled amount of 20mg per vial for laboratory research. ChoicePeps discusses this product family under the CP-R3 designation in its Research Library.

Specifications

• Product: CP-Reta 20mg
• Label amount: 20mg per vial
• Form: lyophilized powder
• Intended use: in-vitro laboratory research only

The 20mg label amount identifies this product option. It is not a concentration in mg/mL; the laboratory’s measured batch result is reported separately below.

Current batch and COA

BT Labs tested batch CP-RT20-2608 on August 28, 2026. Report COA261200-004 is dated September 2, 2026.

• Identity: batch-specific FTIR identification is documented in the laboratory report, which also notes excipients/fillers.
• HPLC purity: 99.6%
• HPLC potency: 20.9mg

These results apply to the sample tested from this batch, not every vial or future batch. The 20.9mg result is measured peptide potency, separate from the 20mg label amount. This testing does not establish sterility or endotoxin status.

Read the CP-RT20-2608 COA summary   Match your lot number to the Currently Shipping COAs or the ChoicePeps batch ledger.

Research context and other label amounts

For educational background, see the CP-R3 research overview. Research background does not establish clinical benefits from a ChoicePeps vial.

Other product options include CP-Reta 30mg and CP-Reta 60mg. Each page provides its own labeled amount and batch documentation; these links do not imply differences in efficacy or provide dosing guidance.

Research use only

For in-vitro laboratory research only. Not for human or veterinary use, diagnosis or treatment. Read the research-use-only information.